Published in Am J Psychiatry on December 01, 2006
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. J Nerv Ment Dis (2014) 0.99
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull (2008) 0.85
Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. Schizophr Bull (2008) 0.78
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell (2007) 8.99
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (2013) 8.20
Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature (2009) 8.12
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet (2007) 7.85
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet (2012) 4.59
Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry (2011) 4.29
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci (2010) 3.47
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 3.29
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry (2008) 3.23
n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr (2010) 3.09
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
Human postmortem tissue: what quality markers matter? Brain Res (2006) 2.92
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci (2010) 2.84
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry (2006) 2.63
Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry (2012) 2.61
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry (2008) 2.53
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry (2002) 2.47
Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature (2010) 2.46
Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull (2006) 2.46
The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry (2013) 2.39
Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol Psychiatry (2012) 2.33
Uncovering early response of gene regulatory networks in ESCs by systematic induction of transcription factors. Cell Stem Cell (2009) 2.32
Conflict of interest. Am J Psychiatry (2006) 2.30
Exacerbation of schizophrenia by varenicline. Am J Psychiatry (2007) 2.27
The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum (2007) 2.25
Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry (2009) 2.25
Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. Am J Psychiatry (2014) 2.21
Fidelity outcomes in the National Implementing Evidence-Based Practices Project. Psychiatr Serv (2007) 2.21
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) (2004) 2.19
The Internet-based MGS2 control sample: self report of mental illness. Am J Psychiatry (2010) 2.05
Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry (2011) 2.02
Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol (2008) 2.02
Rapid induction of therapeutic hypothermia using convective-immersion surface cooling: safety, efficacy and outcomes. Resuscitation (2010) 1.93
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron (2011) 1.92
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
Decoding the massive genome of loblolly pine using haploid DNA and novel assembly strategies. Genome Biol (2014) 1.90
Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. Am J Hum Genet (2006) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry (2012) 1.85
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
Medicaid and mental health: be careful what you ask for. Health Aff (Millwood) (2003) 1.83
Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron (2011) 1.82
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) (2005) 1.82
The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol (2011) 1.82
Evidence-based practices: setting the context and responding to concerns. Psychiatr Clin North Am (2003) 1.78
Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum (2007) 1.76
Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.76
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry (2007) 1.75
The choice of drugs for schizophrenia. N Engl J Med (2006) 1.75
How adolescents perceive the stigma of mental illness and alcohol abuse. Psychiatr Serv (2005) 1.73
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A (2005) 1.72
A political history of federal mental health and addiction insurance parity. Milbank Q (2010) 1.70
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med (2013) 1.70
Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol (2007) 1.65
Maintaining informed consent validity during lengthy research protocols. IRB (2008) 1.62
Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry (2012) 1.61
AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry (2008) 1.60
Project IMPACT: a report on barriers and facilitators to sustainability. Adm Policy Ment Health (2006) 1.58
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
The state policy context of implementation issues for evidence-based practices in mental health. Psychiatr Serv (2007) 1.52
Evolution of genome size and complexity in Pinus. PLoS One (2009) 1.52
Assisting Social Security Disability Insurance beneficiaries with schizophrenia, bipolar disorder, or major depression in returning to work. Am J Psychiatry (2013) 1.51
Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry (2004) 1.49
Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology (2009) 1.47
Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry (2010) 1.45
Conflict of interest, round 2. Am J Psychiatry (2006) 1.44
Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.43
The use of depot medications in the treatment of schizophrenia. Am J Psychiatry (2010) 1.43
Neuronal dysfunction and schizophrenia symptoms. Am J Psychiatry (2007) 1.42
Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia. Schizophr Res (2007) 1.42
Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. Am J Psychiatry (2015) 1.40
Priming defense genes and metabolites in hybrid poplar by the green leaf volatile cis-3-hexenyl acetate. New Phytol (2008) 1.40
Mental health policy and psychotropic drugs. Milbank Q (2005) 1.38
Psychotherapy in the Journal: what's missing? Am J Psychiatry (2006) 1.38
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology (2004) 1.37
Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry (2006) 1.36
Trends in mental health cost growth: an expanded role for management? Health Aff (Millwood) (2009) 1.35
Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry (2013) 1.35